Ferraro, Emanuela
Singh, Jasmeet http://orcid.org/0000-0003-2318-4546
Patil, Sujata
Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Modi, Shanu
Chandarlapaty, Sarat http://orcid.org/0000-0003-4532-8053
Barrio, Andrea V.
Malani, Rachna
Mellinghoff, Ingo K. http://orcid.org/0000-0002-4347-8149
Boire, Adrienne http://orcid.org/0000-0002-9029-1248
Wen, Hannah Y.
Brogi, Edi http://orcid.org/0000-0003-4737-8468
Seidman, Andrew D.
Norton, Larry
Robson, Mark E. http://orcid.org/0000-0002-3109-1692
Dang, Chau T. http://orcid.org/0000-0001-5133-2265
Article History
Received: 17 March 2021
Accepted: 1 November 2021
First Online: 22 March 2022
Competing interests
: P.R. received speakers’ bureau and consultancy/advisory role from Novartis, Foundation Medicine, AstraZeneca, Epic Sciences, Inivata, Natera, Tempus and contracted research funding from Grail, Illumina, Novartis, Epic, Sciences, ArcherDx. S.M. received research support from Genentech, Daiichi-Sankyo, Astrazeneca, Seattle Genetics; speakers bureau from Genentech, Daiichi-Sankyo, Astrazeneca, Seattle Genetics; advisory honoraria form Macrogenics, Daiichi-Sankyo, Astrazeneca, Seattle Genetics. S.C. received contracted research funding from Daiichi-Sankyo, Paige.ai, Novartis, Sanofi, Lilly. A.B received a role in the scientific Advisory Board of Evren Scientific (unpaid); patents: Sloan Kettering Institute, assignee for the following United States Provisional Applications: No.: 62/258,044. November 20, 2015, No.: 10413522, awarded September 17, 2019 and No.: 63/052,139. A.D.S received honoraria as speaker and consultant from Genentech. M.E.R received honoraria from Research to Practice, Intellisphere and physicians’ Education Resource, consulting or advisory role from AstraZeneca (uncompensated), Change Healthcare, Daiichi-Sankyo (uncompensated), Epic Sciences (uncompensated), Merck (uncompensated), Pfizer (uncompensated) and research funding from AbbVie (institution), AstraZeneca (Institution), Invitae (Institution, in-kind), Merck (Institution) and Pfizer (Institution). C.T.D received research funding and personal fees from Genentech/Roche and Puma Technology. The remaining authors declare no competing interests.